Iris Mhlanga

Iris Mhlanga

Auto-generated profile, based on publicly available information

Iris Mhlanga

University of Nottingham

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
PBPhilip M Bath
Philip M Bath
IMIris Mhlanga
Iris Mhlanga
LWLisa J Woodhouse
Lisa J Woodhouse
FDFergus Doubal
Fergus Doubal
KOKatherine Oatey
Katherine Oatey
JWJoanna M Wardlaw
Joanna M Wardlaw
Background Cerebral small vessel disease (SVD) causes lacunar strokes (25% of all ischaemic strokes), physical frailty and cognitive impairment and vascular and mixed dementia. There is no specific treatment to prevent progression of SVD. Methods The LACunar Intervention Trial-2 is an investigator-initiated prospective randomised open-label blinded-endpoint phase II feasibility study assessing cilostazol and isosorbide mononitrate for preventing SVD progression. We aimed to recruit 400 patients with clinically evident lacunar ischaemic stroke and randomised to cilostazol, isosorbide mononitrate, both or neither, in addition to guideline secondary ischaemic stroke prevention, in a partial factorial design. The primary outcome is feasibility of recruitment and adherence to medication; key secondary outcomes include: drug tolerability; recurrent vascular events, cognition and function at 1 year after randomisation; and safety (bleeding, falls, death). Data are number (%) and median (IQR). Results The trial commenced on 5 February 2018 and ceased recruitment on 31 May 2021 with 363 patients randomised, with the following baseline characteristics: average age 64 (56.0, 72.0) years, female 112 (30.9%), stroke onset to randomisation 79.0 (27.0, 244.0) days, hypertension 267 (73.6%), median blood pressures 143.0 (130.0, 157.0)/83.0 (75.0, 90.0) mm Hg, current smokers 67 (18.5%), educationally achieved end of school examinations (A-level) or higher 118 (32.5%), modified Rankin scale 1.0 (0.0, 1.0), National Institutes Health stroke scale 1.0 (1.4), Montreal Cognitive Assessment 26.0 (23.0, 28.0) and total SVD score on brain imaging 1.0 (0.0, 2.0). This publication summarises the baseline data and presents the statistical analysis plan. Summary The trial is currently in follow-up which will complete on 31 May 2022 with results expected in October 2022. Trial registration number ISRCTN14911850.

1 January 2026 in Cerebrovascular Diseases Extra
Verified
Journal Article
Open access
JBJacqueline K. Benfield
Jacqueline K. Benfield
LELisa F. Everton
Lisa F. Everton
LWLisa J. Woodhouse
Lisa J. Woodhouse
IMIris Isheanesu Mhlanga
Iris Isheanesu Mhlanga
CLCorinne Latulipe
Corinne Latulipe
PBPhilip M. Bath
Philip M. Bath
Introduction: Acute ischaemic stroke and primary intracerebral haemorrhage are complicated by oropharyngeal dysphagia in more than 50% of patients. Currently, there are no definitive treatments for post-stroke dysphagia (PSD). Pharyngeal electrical stimulation (PES) can drive long-term beneficial changes in the cortical control of swallowing with functionally relevant reorganisation of the swallowing cortex correlating with reduced dysphagia. Methods: The pharyngeal electrical stimulation for acute stroke dysphagia trial (PhEAST) is an international prospective randomised open-label blinded-endpoint parallel-group phase 4 superiority effectiveness trial. A total of 638 patients with PSD and dependency on nasogastric tube feeding are being recruited within 2–31 days of ictus. Participants are recruited from the UK and Austria and randomised to 6 days of optimised PES (given for 10 min each day) vs. no PES on top of standard care. The primary outcome is the dysphagia severity rating scale, an assessment of swallowing impairment, measured locally on day 14 and centrally at day 90 by trained observers masked to treatment and analysed using repeated measures regression analysis. Secondary outcomes include: functional oral intake scale, feeding status scale, international dysphagia diet standardisation initiative scale, presence of a feeding tube, pneumonia, antibiotic use, health-related quality of life, dependency, disability, frailty, mood, cognition, global impact and health economics at days 14, 90, 180, and 365. Safety measures include death and serious adverse events. Conclusion: PhEAST has recruited more than 574 participants from 45 hospitals in the UK and Austria; recruitment will be complete at the end of October 2026. The attached Supplement summarises the protocol and follows the EQUATOR SPIRIT guideline.

9 September 2025 in Research Square
Verified
Preprint
Open access
PDF file
LWLisa J Woodhouse
Lisa J Woodhouse
IMIris Mhlanga
Iris Mhlanga
ABAmanda Buck
Amanda Buck
LGLucy Gray
Lucy Gray
AHAmanda Hedstrom
Amanda Hedstrom
PBPhilip Bath
Philip Bath
Background High blood pressure is associated with a poor outcome after stroke. Trials of transdermal glyceryl trinitrate (GTN), a nitric oxide donor, have suggested that treatment between 3 and 5 hours might improve functional outcome. Methods We randomly assigned hospitalised patients with an acute ischaemic or haemorrhagic stroke to 2 days of transdermal glyceryl trinitrate (GTN, 5 mg/day) or sham, started between 3 and 5 hours after onset. The primary feasibility outcome was recruitment rate; proof of concept was assessed by central observers blinded to treatment assignment at 90 days using the modified Rankin Scale (mRS). Data are number (%), median [interquartile range] or mean (standard deviation). Comparisons by adjusted multiple linear regression. Findings 39 of an intended 120 participants were recruited; common exclusions were presentation >5 hours of onset or out of researcher working hours, no eligible symptoms/signs or an unclear onset time. Mean age 72 (13) years, female 41%, blood pressure 161.8(18.4)/80.8(14.9) mmHg, time from onset at baseline 216 [186, 251] minutes. The fall in blood pressure over 24 hours did not differ between GTN versus sham. Headache was more common with GTN but there was no difference in serious adverse events. mRS at 3 months did not differ between the groups. Interpretation Recruitment limitations prevented demonstration of feasibility for patients in the time window of 3-5 hours post ictus. GTN appeared safe and showed some evidence of proof-of-concept. A multicentre trial needs to further test this hypothesis. Registration ISRCTN17654248 Date: 31/3/2021

1 January 2026 in Cerebrovascular Diseases Extra
Verified
Journal Article
Open access
LWLisa J. Woodhouse
Lisa J. Woodhouse
IMIris Mhlanga
Iris Mhlanga
ABAmanda Buck
Amanda Buck
LGLucy Gray
Lucy Gray
AHAmanda Hedstrom
Amanda Hedstrom
PBPhilip M. Bath
Philip M. Bath
Introduction: High blood pressure (BP) is associated with a poor outcome after stroke. Trials of transdermal glyceryl trinitrate (GTN), a nitric oxide donor, have suggested that treatment between 3 and 5 h might improve functional outcome. Methods: We randomly assigned hospitalised patients with an acute ischaemic or haemorrhagic stroke to 2 days of transdermal GTN (5 mg/day) or sham, started between 3 and 5 h after onset. The primary feasibility outcome was recruitment rate; proof-of-concept (PoC) was assessed at 90 days by central observers blinded to treatment assignment using the modified Rankin Scale (mRS). Data are number (%), median [interquartile range], or mean (standard deviation). Comparisons were assessed by multiple linear regression. Results: Thirty-nine of an intended 120 participants were recruited. A total of 3,314 people were excluded, commonly related to presentation >5 h of onset or outside of researcher working hours, no eligible symptoms/signs or an unclear onset time. Mean age was 72 (SD 13) years, females were 41%, BP was 161.8 (18.4)/80.8 (14.9) mm Hg, and time from onset at baseline was 216 [186, 251] minutes. The fall in BP over 24 h did not differ between GTN versus sham. mRS at 3 months did not differ between the groups (difference in means, DIM −0.20, 95% confidence intervals −1.30, 0.90; p = 0.72). GTN was associated with improved cognition on the telephone interview of cognition scale (DIM 8.0, 95% CI 1.3, 14.8; p = 0.020). Although headache was more common, GTN was associated with fewer serious adverse events (p = 0.020). Conclusion: Recruitment limitations in this small single-centre trial prevented demonstration of feasibility for patients in the time window of 3–5 h post ictus. GTN demonstrated some evidence of PoC and was safe. A multicentre trial needs to further test this hypothesis.

6 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PBPhilip M. Bath
Philip M. Bath
LILACI-2 Trial Investigators
LACI-2 Trial Investigators
LWLisa J Woodhouse
Lisa J Woodhouse
IMIris Mhlanga
Iris Mhlanga
JBJohn M Bamford
John M Bamford
JWJoanna M Wardlaw
Joanna M Wardlaw
Background: Lacunar stroke, a type of cerebral small vessel disease (cSVD), causes cognitive decline and dependency. The LACunar Intervention Trial-2 (LACI-2) trial showed that 12 months of treatment with isosorbide-mononitrate (ISMN) and/or cilostazol improved these outcomes. We tested whether this effect was present at 6 months, a pre-specified analysis. Methods: LACI-2 assessed the feasibility, safety and proof-of-concept of one year of ISMN (40-60mg) and/or cilostazol (200 mg) using a prospective randomised open-label blinded-endpoint 2×2-factorial phase-2b design. Participants aged>30yrs had clinical lacunar stroke, compatible brain imaging and capacity to consent. Key outcomes included cognition (Diagnostic and Statistical Manual version 5-7-level, DSM5-7L), dependency, vascular events, mood, stroke impact and a global analysis of these. Results: Baseline characteristics were balanced across 363 participants: median age 64 [56-72] years, females 31% and median onset-to-randomisation 79 [27-244] days. At 6 months, participants allocated to ISMN vs control had fewer vascular-cognition-dependency events (adjusted odds ratio, aOR 0.74, 95% confidence intervals 0.55-0.99) and an improved stroke impact scale score (Mann-Whitney difference, MWD - 0.15, 95% CI −0.25, −0.05) and global analysis (MWD −0.06, 95% CI −0.11, −0.01). Cilostazol vs control reduced cognitive impairment (DSM5-7-level scale, acOR 0.64, 95% CI 0.41-0.99). Combined ISMN/cilostazol vs control (n=181) had improved cognition (DSM5-7L acOR 0.40, 95% CI 0.21-0.78) and mood (Zung aMD −6.94, 95% CI −12.25, −1.64), reduced stroke impact (−0.23, 95% CI −0.37, −0.09) and a better global outcome (MWD −0.10, 95% CI −0.17, −0.03). Conclusions: Improvements in cognitive and functional outcomes were seen within 6 months of ISMN and/or cilostazol. Registration: ISRCTN14911850 : https://www.isrctn.com/ISRCTN14911850

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
PBPhilip M. Bath
Philip M. Bath
LWLisa J. Woodhouse
Lisa J. Woodhouse
IMIris Mhlanga
Iris Mhlanga
JBJohn Bamford
John Bamford
VCVera Cvoro
Vera Cvoro
JWJoanna M Wardlaw
Joanna M Wardlaw
Background: Lacunar stroke can cause cognitive decline and dependency. The LACI‐2 (Lacunar Intervention Trial‐2) trial showed that 12 months of treatment with isosorbide‐mononitrate (ISMN) or cilostazol improved these outcomes. We tested whether this effect was present at 6 months. Methods: LACI‐2 was a prospective randomized open‐label blinded‐end point 2×2‐factorial phase‐2b trial assessing feasibility, safety, and proof‐of‐concept of 1 year of ISMN (40–60 mg) or cilostazol (200 mg). Participants aged >30 years had clinical lacunar stroke, compatible neuroimaging, and capacity to consent. The primary clinical outcome was the composite of stroke, myocardial infarction, dependency (modified Rankin Scale score >2), cognitive impairment ( Diagnostic and Statistical Manual version 5, 7‐level >0) and death; key secondary outcomes included the composite components, mood and stroke impact scale. Global analysis of the stroke impact scale was analyzed using the Wei–Lachin test with result given as Mann–Whitney difference. Results: Baseline characteristics were balanced across 363 participants: median age 64 (56–72) years, 31% female, and median onset to randomization 79 (27–244) days. At 6 months, participants allocated to ISMN versus control had fewer composite events (adjusted odds ratio [OR], 0.74 [95% CI, 0.55–0.99]) and improved stroke impact (Mann–Whitney difference, −0.15 [95% CI −0.25 to −0.05]). Cilostazol versus control improved cognition ( Diagnostic and Statistical Manual version 5, 7‐level scale, adjusted common OR, 0.64 [95% CI, 0.41–0.99]). ISMN/cilostazol versus control improved cognition ( Diagnostic and Statistical Manual version 5, 7‐level adjusted common OR, 0.40 [95% CI, 0.21–0.78]), mood (Zung adjusted mean difference, −6.94 [95% CI, −12.25 to −1.64]) and global stroke impact (Mann–Whitney difference, −0.23 [95% CI, −0.37 to −0.09]). Conclusions: A reduction in the composite outcome, cognitive impairment, dependency, and stroke impact was seen within 6 months of starting ISMN or cilostazol. Registration: URL: www.isrctn.com ; Unique Identifier: ISRCTN14911850.